The rising impact of biomarkers in early clinical development
Drug Target Review
APRIL 7, 2025
However, standard preclinical safety assessment studies may not accurately predict adverse events in humans, particularly with emerging modalities like precision medicine targeting human antigens or genes not present in preclinical species. For use as endpoints, biomarkers must be correlated to a valid clinical outcome.
Let's personalize your content